Quintiles has initiated a plan to improve the development of biomarker-targeted therapies through a new approach that promotes the genomic “pre-profiling” of cancer patients. Quintiles, with the participation of U.S. Oncology Research, supported by McKesson Specialty Health and The U.S. Oncology Network, will study operational feasibility and clinical benefits of an upfront approach to the genomic profiling of tumors from metastatic colorectal cancer (mCRC) patients. The study will investigate h...